These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12136428)

  • 21. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
    Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
    Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice.
    Wolschek MF; Thallinger C; Kursa M; Rössler V; Allen M; Lichtenberger C; Kircheis R; Lucas T; Willheim M; Reinisch W; Gangl A; Wagner E; Jansen B
    Hepatology; 2002 Nov; 36(5):1106-14. PubMed ID: 12395320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoinduction of tumor necrosis factor-alpha in FRTL-5 rat thyroid cells.
    Mori K; Yoshida K; Komatsu A; Tani J; Nakagawa Y; Hoshikawa S; Ito S
    J Endocrinol; 2005 Oct; 187(1):17-24. PubMed ID: 16214937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
    Curnis F; Sacchi A; Corti A
    J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vpr-expressing plasmid by in vivo electroporation.
    McCray AN; Ugen KE; Muthumani K; Kim JJ; Weiner DB; Heller R
    Mol Ther; 2006 Nov; 14(5):647-55. PubMed ID: 16950655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polyethylenimine-mediated in vivo gene transfer of a transmembrane superantigen fusion construct inhibits B16 murine melanoma growth.
    Jeudy G; Salvadori F; Chauffert B; Solary E; Vabres P; Chluba J
    Cancer Gene Ther; 2008 Nov; 15(11):742-9. PubMed ID: 18617917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
    Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
    Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma cell line.
    Giermasz A; Grzela T; Nowis D; Makowski M; Czajka A; Stoklosa T; Lasek W; Dabrowsk A; Wiznerowicz M; Mackiewicz A; Jakóbisiak M
    Anticancer Res; 2001; 21(6A):4001-4. PubMed ID: 11911283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs.
    López P; Gómez J; Mozo L; Gutiérrez C; Suárez A
    Arthritis Res Ther; 2006; 8(2):R42. PubMed ID: 16507146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis.
    Egberts JH; Cloosters V; Noack A; Schniewind B; Thon L; Klose S; Kettler B; von Forstner C; Kneitz C; Tepel J; Adam D; Wajant H; Kalthoff H; Trauzold A
    Cancer Res; 2008 Mar; 68(5):1443-50. PubMed ID: 18316608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression.
    Aigner A; Fischer D; Merdan T; Brus C; Kissel T; Czubayko F
    Gene Ther; 2002 Dec; 9(24):1700-7. PubMed ID: 12457284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
    Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
    Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optical imaging of transferrin targeted PEI/DNA complexes in living subjects.
    Hildebrandt IJ; Iyer M; Wagner E; Gambhir SS
    Gene Ther; 2003 May; 10(9):758-64. PubMed ID: 12704414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor regression after systemic administration of transferrin-targeted TNFalpha plasmid-dendrimer conjugates.
    Park K
    J Control Release; 2010 Apr; 143(2):167. PubMed ID: 20193721
    [No Abstract]   [Full Text] [Related]  

  • 38. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo.
    Hui W; Rowan AD; Richards CD; Cawston TE
    Arthritis Rheum; 2003 Dec; 48(12):3404-18. PubMed ID: 14673992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model.
    Yoo J; Choi S; Hwang KS; Cho WK; Jung CR; Kwon ST; Im DS
    J Gene Med; 2006 Feb; 8(2):163-74. PubMed ID: 16144019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine-dependent invasiveness in B16 murine melanoma cells: role of uPA system and MMP-9.
    Bianchini F; D'Alessio S; Fibbi G; Del Rosso M; Calorini L
    Oncol Rep; 2006 Mar; 15(3):709-14. PubMed ID: 16465434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.